<unk>  (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010. It is formulated as a 3% ophthalmic solution of the tetrasodium salt. Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.
Diquafosol
Caphosol
Vilanterol
Desloratadine
Cromoglicic acid
Coralmyn
Tiratricol
Desmethylchlorotrianisene